Fox Chase's Eric M. Horwitz Elected President of American Brachytherapy Society
Philadelphia (June 15, 2009) – Eric M. Horwitz, MD, acting chairman of the radiation oncology department at Fox Chase Cancer Center, has been elected president of the American Brachytherapy Society (ABS). Horwitz was elected as vice president of the ABS in 2008 and served a one year term.
The ABS provides insight, rationale, and research into the use of brachytherapy in the treatment of both malignant and benign conditions. It serves its members by advancing the field of brachytherapy through excellence in education, research and clinical practice. Currently brachytherapy is being used primarily to treat prostate, breast and cervical cancers.
Horwitz is recognized nationally for his expertise in treating patients with prostate cancer. At Fox Chase, he has developed advanced programs using intensity-modulated radiation therapy (IMRT), image-guided radiation therapy and brachytherapy. These include high-dose-rate (HDR) brachytherapy for prostate cancer, a treatment using temporary radiation implants. As a result, Fox Chase was the first institution in the Northeast United States to offer HDR implants to men with prostate cancer.
In addition, Horwitz integrated the use of an MRI treatment simulator into prostate cancer treatment planning for permanent, low-dose rate prostate implants and IMRT. Fox Chase was the first in the world to use MRI in radiation treatment planning.
He has published extensively in peer-reviewed journals and is a co-author of several chapters in various oncology texts. Horwitz serves on the editorial board of the journal Brachytherapy. He is also active in the American Society of Therapeutic Radiology and Oncology and the American College of Radiology.
Horwitz received his MD from Albany Medical College in New York after earning his undergraduate degree at the University of Pennsylvania in Philadelphia. He completed both his internship and residency at William Beaumont Hospital in Royal Oak, Mich. He was chief resident in radiation oncology there before he came to Fox Chase in 1997.
For more information about the ABS, visit their website at www.americanbrachytherapy.org.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.